What's next for Ebos after the end of that Chemist Warehouse contract

What's next for Ebos after the end of that Chemist Warehouse contract
CEO John Cullity says there isn't double-digit growth to be found in animal or healthcare in Australasia. (Image: Ebos)
Rebecca Stevenson
Ebos chief executive John Cullity says the firm must hunt outside of Australasia for double-digit growth. The dual-listed healthcare and pharmaceutical marketer and wholesaler was looking for growth outside its traditional powerhouse pharmaceutical business, Cullity said. He said Ebos’s pharmacy business in NZ and Australia was solid and stable but had relatively low growth. “Double-digit growth rates are going to be very hard, so we need to broaden the group's base of earnings outside of Australia and New Zealand...

More Markets

Your mid-year investment health check
Markets

Simon Robertson: Your mid-year investment health check

What should you really be looking for from your fundie? 

Simon Robertson 05 Jul 2025
Tourism Holdings stalls as NZ sharemarket ends week on high
Markets Market Close

Tourism Holdings stalls as NZ sharemarket ends week on high

The NZ sharemarket bounced back as large-cap stocks balanced gains and losses.

Tom Raynel 04 Jul 2025
Forsyth Barr shifts Turners Automotive to neutral
Markets

Forsyth Barr shifts Turners Automotive to neutral

The company has delivered five consecutive years of record earnings.

Rebecca Howard 04 Jul 2025
Vital board backs Tait takeover
Markets

Vital board backs Tait takeover

Vital’s board has unanimously recommended that shareholders and option holders accept a full takeover offer from Tait Communications, despite their view that it undervalues the company.In May, Vital shares rallied after it disclosed that Tait, a Christchurch-based critical commun...

Gregor Thompson 04 Jul 2025